U.S. Sex Reassignment Hormone Therapy Market (By Gender Transition: Male-To-Female, Female-To-Male; By Type: Puberty Blockers, Estrogen; By Distribution Channel) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The U.S. sex reassignment hormone therapy market size was estimated at around USD 1.72 billion in 2023 and it is projected to hit around USD 2.57 billion by 2033, growing at a CAGR of 4.08% from 2024 to 2033.

Key Pointers

• By Gender Transition, the male-to-female segment held the largest revenue share of 54% in 2023.
• By Type, the estrogen segment generated the maximum market share of 42% in 2023.
• By Distribution Channel, the retail pharmacies segment contributed the largest market share of 58% in 2023. 

U.S. Sex Reassignment Hormone Therapy Market Growth Factors

The growth of the U.S. sex reassignment hormone therapy market is propelled by an increasing societal awareness and acceptance of transgender rights have led to greater demand for gender-affirming healthcare services, including hormone therapy. Additionally, advancements in medical technology and formulations have improved the efficacy and safety of hormone treatments, making them more accessible and appealing to transgender individuals. Moreover, evolving healthcare policies and regulations aimed at expanding insurance coverage and reducing barriers to care have contributed to market growth. Furthermore, the growing collaboration between pharmaceutical companies, healthcare providers, and advocacy groups has fostered innovation and supported initiatives to address the specific needs of transgender patients. 

Report Scope of the U.S. Sex Reassignment Hormone Therapy Market

U.S. Sex Reassignment Hormone Therapy Market Trends:

• Increasing Demand: Growing societal acceptance and awareness of transgender rights have led to a rising demand for gender-affirming healthcare services, including hormone therapy.
• Advancements in Formulations: Ongoing advancements in medical technology and formulations have resulted in improved efficacy, safety, and administration methods of hormone treatments, catering to the diverse needs of transgender individuals.
• Telemedicine Adoption: The adoption of telemedicine and virtual care platforms has facilitated greater accessibility to hormone therapy consultations and monitoring, particularly in underserved or remote areas.
• Personalized Treatment Approaches: Healthcare providers are increasingly adopting personalized treatment approaches, tailoring hormone therapy regimens to individual patient needs and preferences for enhanced efficacy and patient satisfaction.
• Rising Research and Development: Pharmaceutical companies and research institutions are investing significantly in research and development efforts aimed at developing novel hormone therapy formulations with improved therapeutic outcomes and reduced side effects.
• Expansion of Healthcare Coverage: Efforts to expand insurance coverage for gender-affirming healthcare services, including hormone therapy, are underway, driven by advocacy initiatives and evolving healthcare policies aimed at reducing financial barriers to care.
• Integration of Mental Health Support: There is a growing recognition of the importance of integrated mental health support as part of hormone therapy programs, with an emphasis on addressing the psychosocial aspects of gender transition and promoting holistic patient well-being.
• Inclusive Healthcare Practices: Healthcare providers are adopting more inclusive practices and creating welcoming environments for transgender patients, including gender-affirming language, cultural competency training, and sensitivity to diverse gender identities.

Gender Transition Insights

Based on gender transition, the market is segmented into male-to-female (MTF) and female-to-male (FTM). The male-to-female segment dominated the market in 2023 with a share of 54% and is anticipated to witness the fastest growth over the forecast period owing to the increasing awareness regarding the therapies and the presence of advanced hormone therapies in the U.S. According to a study published by NCBI, the individuals diagnosed with gender dysphoria are estimated to be 460 per 100, 000 with a high prevalence of male to female individuals. The increasing male-to-female population is driving the market growth.

Furthermore, according to a study published by the Journal of Internal Medicine in January 2023, the population-based gender incongruence range for birth-assigned males is between 0.5% to 1.3%. The aforementioned factor, coupled with technological advancements in sex reassignment hormone therapies, is anticipated to drive segment growth over the forecast period.

Type Insights

Based on type, the market is segmented into puberty blockers, estrogen, and testosterone. The estrogen segment dominated the market in 2023 with a revenue share of 43%. Estrogen drugs are the primary hormone treatment for transwomen seeking sex reassignment. The prescription of estrogens to transgender women or trans feminine individuals (MTF) follows a similar approach to hormone replacement therapy for postmenopausal women, albeit with slightly higher doses.

Testosterone is another lucrative segment in the market. It is commonly used to induce masculinizing effects in transgender men. The availability of a wide range of product forms as per individual compatibility increases product adoption in the space.

Distribution Channel Insights

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment dominated with a revenue share of 58% in 2023. The segment growth is attributed to the rising awareness regarding the availability of hormone therapy products coupled with the convenience and accessibility of retail pharmacies, making it easier for individuals to access hormone therapy prescriptions and related medications.

The other segment comprises online platforms offering online distribution of sex reassignment hormone therapy products and is anticipated to grow fastest at a CAGR of 5.87% from 2024 to 2033. This growth is attributed to increased internet accessibility, advancements in telemedicine, and changing attitudes toward seeking medical advice and treatments online.

Moreover, the convenience and privacy offered by online platforms may make them appealing to individuals seeking sex reassignment hormone therapy. Additionally, online platforms provide access to specialized healthcare providers who may not be geographically accessible to certain individuals. The aforementioned factors are anticipated to drive segment growth over the forecast period.

U.S. Sex Reassignment Hormone Therapy Market Key Companies

• Viatris Inc.
• AbbVie Inc.
• ASCEND Therapeutics US, LLC.
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• Endo International plc

U.S. Sex Reassignment Hormone Therapy Market Segmentations:

By Gender Transition 

• Male-To-Female (MTF)
• Female-To-Male (FTM)

By Type 

• Puberty Blockers
• Estrogen
• Testosterone

By Distribution Channel 

• Hospital Pharmacies
• Retail Pharmacies
• Others